Kraków, 3rd December 2020

REQUEST FOR QUOTATION No 03 12 2020 D

for a service: Stimulation and fixation of murine blood

as a part of the project titled „Novel, small molecule immunomodulating agents in treatment-resistant cancers" co-financed by the European Union Funds under Measure 1.1.1 "Industrial research and development work carried out by enterprises" of the OPERATIONAL PROGRAMME SMART GROWTH 2014-2020.

I. ORDERING PARTY:

Ryvu Therapeutics S.A.
ul. Leona Sternbacha 2,
30-394 Kraków
VAT EU: 679 29 42 955

II. DESCRIPTION OF THE ORDER:

1. Contractor should make an offer for service presented below:

Murine blood stimulation and fixation will be performed based on the **exemplary protocol**:

1. Collect blood samples into heparin-coated vials meeting the following specification:
   Sodium heparin blood collection vials
   • for small volume blood collections from 250-500 µl;
   • with push cap;
   • dimensions: 8 mm x 43mm;
2. Transfer 20ul of blood/animal into single well of PP 96-well V-bottom plate (or Eppendorf-like tubes).
3. Add 5ul/well (or Eppendorf-like tube) of 5x conc. anti-CD3 (25 µg/ml, final anti-CD3 concentration is 5 µg/ml) in plain RPMI. Incubate 60min, 37°C at 5%CO_2. If using Eppendorf-like tubes, they should not be tightly closed during incubation.
4. During stimulation of samples prepare assay buffer as follows:

Assay buffer	Stock solution	diluent
1x Lyse/Fix buffer	5x concentrated	ultrapure water (from water purification system)

Place the 1x Lyse/Fix buffer to water bath at 37°C for 25 minutes.

5. Fix samples immediately with warm 1x Lyse/Fix buffer to stop signaling cascades (add 180ul Lyse/Fix/well to all samples).

6. Incubate the cells at 37°C for 10 to 12 minutes.
7. Freeze and store the samples at -80°C and ship to Ryvu Therapeutics S.A.

Lyse/fix buffer must meet the following minimal specification:

• for use with intracellular flow cytometry;
• reported to preserve the light scattering properties of the cell and may be used on human and mouse whole blood;
• Storage Buffer: Aqueous buffered solution containing formaldehyde and proprietary ingredients;
• can be used for lysing red blood cells and for fixing leukocytes in one step;
• can be stored at room temperature;

Antibodies to be used in the protocol must meet the following minimal specification:

Purified anti-mouse CD3ε monoclonal antibody

- Isotype: Armenian Hamster IgG;
- Clone: 145-2C11;
- formulation: 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative;
- endotoxin level is <0.01 EU/µg of the protein (<0.001 ng/µg of the protein) as determined by the LAL test;
- concentration: between 2 mg/ml and 3 mg/l;
- antibody was purified by affinity chromatography;

Purified Armenian Hamster IgG Isotype control antibody

- Isotype: Armenian Hamster IgG;
- Clone: HTK888;
- formulation: 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative;
- endotoxin level is <0.01 EU/µg of the protein (<0.001 ng/µg of the protein) as determined by the LAL test;
- concentration: between 2 mg/ml and 3 mg/l;
- antibody was purified by affinity chromatography;

The material (blood from mice) will be provided by the Sponsor.

Contractor should provide all the reagents and necessary equipment to perform the service according to the protocol.

Contractor should declare a possibility to process **up to 1000 blood samples within 14 months** according to the protocol listed above. It is assumed that there may be **up to 10 shipments of the processed (stimulated and fixed) blood samples from Contractor to Sponsor within 14 months.**

Contractor should specify the costs by filling the table (Appendix 1).

2. CPV code: 73110000-6
3. It is ~~possible~~/not possible to make an offer for a part of an order.
4. It is ~~possible~~/not possible to make a variant offer

III. OTHER REQUIREMENTS

1. **Offer validity period** – at least **till 28th February 2022.**
2. **Payment term** - at least **30 calendar days** from the invoice date.

In the absence of information about the above requirements (section III), Ordering Party assumes that they comply with the requirements indicated in RFQ.

IV. CONDITIONS FOR PARTICIPATION IN THE PROCEEDINGS:

1. Excluded from the proceedings shall be those Contractors who are personally or equity related to the Ordering Party.*
2. Contractors participating in the proceedings must attach to the offer filled form of compliance with specifications pattern sheet is attached as **Appendix 1** to this RFQ.
3. Additional conditions for participation in the proceedings: **not applicable**

V. DESCRIPTION FOR PREPARING OFFERS:

1. The Contractor should make the offer in Polish or English.
2. The offer has to:
   - **Include contact details**.
   - **Include date of the offer/submission date** (In the absence of the date of issue on the tenders submitted by e-mail, date of receipt will be equivalent to the issue of the offer).
   - **Include price for order** (without VAT/TAX).
     For the purposes of comparing the tenders, the tender price in a foreign currency, will be converted into PLN using the exchange rate given in the Average Exchange Rate Table of the National Bank of Poland (NBP).
   - **Include product description (eg. name, catalog number, etc.)**
   - **Include all the required attachments, indicated in Part IV** (if required)
   - **In contacts with the Ordering Party mention the reference number: 03 12 2020 D**

A lack of any of the above mentioned items will result in rejection of the tender for formal reasons.

VI. EVALUATION OF OFFERS:

The Ordering Party will evaluate valid tenders based on the following criteria:

1. Criterion admitting the tenders for further evaluation:
   - timely submission of the tender;
   - preparation of the tender in accordance with the requirements set out in parts III and V**;**
   - range of functionalities of offered product must comply with the requirements set out in Part II.
2. Criterion for assessing tenders:
   - Price: 100% (sum of prices given in Appendix 1)
3. Method of assessment:
   - The Ordering Party will select the offer with the lowest price among the offers complying with the requirements of the proceedings.

In the case of the same prices from at least two Contractors, the Ordering Party shall appoint the delivery date, and in the absence of a settlement the Contractors will be called to re-present the prices.

VII. DEADLINE OF THE DELIVERY

The Contractor has to estimate a turnaround time of a single study with and without options 1 and 2.

VIII. PLACE AND THE DEADLINE FOR SUBMISSION OF OFFERS:

1. The offer must be submitted by **10th December 2020** by the end of the day (23:59 CET).
2. Offer with required attachments must be sent to the e-mail address: tenders@ryvu.com, by courier or delivered personally to Ryvu Therapeutics S.A., ul. Leona Sternbacha 2, 30-394 Kraków, within deadline set out in clause 1, part VIII.
3. Offers received after the deadline will not be taken into consideration. Decisive will be the date and the time of receipt of the offer by Ordering Party.
4. Contractors may - prior to the deadline for submission of tenders - change or withdraw the offer.
5. The Ordering Party will correct the obvious typographical and accounting errors in the offer, at the same time informing the Contractor by e-mail about the content of the amendment.
6. In the course of comparison and evaluation of offers the Ordering Party may require Contractors to present explanations concerning the content of submitted bids.
7. Inquiry is published on the following websites:
   - http://www.bazakonkurencyjnosci.funduszeeuropejskie.gov.pl

IX. INFORMATION ABOUT THE SELECTION OF BEST OFFER

Information about selecting the best bid will be sent to all Contractors participating in the proceedings and published on website http://www.bazakonkurencyjnosci.funduszeeuropejskie.gov.pl. It will contain the name of the company along with its address and price.

X. AGREEMENT CONCLUSION

The tenderer whose tender is assessed the best shall be obliged to conclude an agreement with the Ordering Party within **14 calendar days** of the date the draft agreement have been sent. If the Contractor whose tender won evades from concluding the agreement the Ordering Party may choose the best tender from among the remaining tenders.

XI. ADDITIONAL INFORMATION

1. The Ordering Party reserves the right to change the content of this request. If the changes can affect the content of tenders submitted in the procedure, the Ordering Party shall extend the tender submission deadline. Any changes made shall be provided promptly to all tenderers to which the request was sent and shall be binding on them.

2. The Ordering Party allows the possibility of granting an order on terms insignificantly different from specified in the query when all the received tenders differ from specification appearing in the query in the same way, and these changes are insignificant and do not affect the proper conduct of the project research, ie.:

- there is incomplete coherence of the product with a description specified in query (eg. purity, form, amount etc.);
- there is incomplete coherence of the conditions for participation in the proceedings with the conditions set out in the request for proposals contained in section III.

3. The Ordering Party reserves the right to cancel this procedure without providing reasons, change the number of products ordered in relation to the number specified in this RFQ, purchase one of parts/items and also to complete the procedure without choosing the winning tender.

For further information please contact with Agnieszka Gacek via e-mail tenders@ryvu.com.

* Equity or personal relationship is understood as relations between the Ordering Party or individuals authorized to take commitments on behalf of the Ordering Party or those acting on behalf of the Ordering Party in order to prepare and implement the contractor selection procedure, and the Contractor, including in particular:

1) being a partner to civil law partnership or commercial law partnership;
2) holding at least 10% of shares if the lower threshold does not result from the law or has not been specified by the Managing Authority for the Operational Programme;
3) being a member of a supervisory or management corporate body, a holder of general commercial power of attorney, an authorized representative;
4) being married to, being in direct consanguinity or affinity, second-degree consanguinity or affinity of the second degree collaterally or by adoption or guardianship.

Appendix 1 to RFQ 03 12 2020 D

Item	**Price**
Cost of performing blood stimulation and fixation should be given, **per single sample** with use either of isotype control antibody or anti-CD3 antibody. Price should include all the reagents needed to properly execute the protocol.	
Shipment of samples (in dry ice) to Poland	